Switch theme
Sign up to access all valuation multiples
Stenocare AS is a Danish company engaged in the cultivation and production of medical cannabis products through pharmacies and hospitals. The Company’s business operations include the distribution and sales of imported products to several markets which also includes local cultivation and production of its medical cannabis products. Stenocare is well positioned to become a market leader in Denmark and a vendor in Europe. The Company is a supplier of medical cannabis oil for patients in Denmerk, Sweden, UK, Australia and Norway. It has an indoor production facility for the cultivation and production of medical cannabis at Randers, Denmark.
2017
8
LTM Revenue $0.6M
LTM EBITDA -$2.0M
$3.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Stenocare has a last 12-month revenue (LTM) of $0.6M and a last 12-month EBITDA of -$2.0M.
In the most recent fiscal year, Stenocare achieved revenue of $0.4M and an EBITDA of -$3.8M.
Stenocare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Stenocare valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.6M | XXX | $0.4M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | -$2.9M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | -828% | XXX | XXX | XXX |
| EBITDA | -$2.0M | XXX | -$3.8M | XXX | XXX | XXX |
| EBITDA Margin | -341% | XXX | -1084% | XXX | XXX | XXX |
| EBIT | -$2.7M | XXX | -$5.2M | XXX | XXX | XXX |
| EBIT Margin | -452% | XXX | -1483% | XXX | XXX | XXX |
| Net Profit | n/a | XXX | -$5.4M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | -1545% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $0.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 14, 2025, Stenocare's stock price is DKK 1 (or $0).
Stenocare has current market cap of DKK 24.1M (or $3.8M), and EV of DKK 21.0M (or $3.3M).
See Stenocare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.3M | $3.8M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 14, 2025, Stenocare has market cap of $3.8M and EV of $3.3M.
Stenocare's trades at 9.4x EV/Revenue multiple, and -0.9x EV/EBITDA.
Equity research analysts estimate Stenocare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Stenocare's P/E ratio is not available.
See valuation multiples for Stenocare and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $3.8M | XXX | $3.8M | XXX | XXX | XXX |
| EV (current) | $3.3M | XXX | $3.3M | XXX | XXX | XXX |
| EV/Revenue | 5.5x | XXX | 9.4x | XXX | XXX | XXX |
| EV/EBITDA | -1.6x | XXX | -0.9x | XXX | XXX | XXX |
| EV/EBIT | -1.2x | XXX | -0.6x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -0.7x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -2.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialStenocare's last 12 month revenue growth is 106%
Stenocare's revenue per employee in the last FY averaged $44K, while opex per employee averaged $0.3M for the same period.
Stenocare's rule of 40 is -229% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Stenocare's rule of X is -77% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Stenocare and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 106% | XXX | 113% | XXX | XXX | XXX |
| EBITDA Margin | -341% | XXX | -1084% | XXX | XXX | XXX |
| EBITDA Growth | -88% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -229% | XXX | -979% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -77% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $44K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 655% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Stenocare acquired XXX companies to date.
Last acquisition by Stenocare was XXXXXXXX, XXXXX XXXXX XXXXXX . Stenocare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Stenocare founded? | Stenocare was founded in 2017. |
| Where is Stenocare headquartered? | Stenocare is headquartered in Denmark. |
| How many employees does Stenocare have? | As of today, Stenocare has 8 employees. |
| Is Stenocare publicy listed? | Yes, Stenocare is a public company listed on CSE. |
| What is the stock symbol of Stenocare? | Stenocare trades under STENO ticker. |
| When did Stenocare go public? | Stenocare went public in 2020. |
| Who are competitors of Stenocare? | Similar companies to Stenocare include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Stenocare? | Stenocare's current market cap is $3.8M |
| What is the current revenue of Stenocare? | Stenocare's last 12 months revenue is $0.6M. |
| What is the current revenue growth of Stenocare? | Stenocare revenue growth (NTM/LTM) is 106%. |
| What is the current EV/Revenue multiple of Stenocare? | Current revenue multiple of Stenocare is 5.5x. |
| Is Stenocare profitable? | Yes, Stenocare is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Stenocare? | Stenocare's last 12 months EBITDA is -$2.0M. |
| What is Stenocare's EBITDA margin? | Stenocare's last 12 months EBITDA margin is -341%. |
| What is the current EV/EBITDA multiple of Stenocare? | Current EBITDA multiple of Stenocare is -1.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
